Expression of synuclein-gamma (SNCG) protein is elevated in the advanced stages of many types of cancers, including breast, ovarian, lung, gastric, liver, esophagus, colon, prostate and others. In breast carcinoma, SNCG is causatively linked to stimulated proliferation, metastasis and drug resistance. A clinical follow-up study indicates that patients with an SNCG-positive breast cancer have a significantly shorter disease-free survival and overall survival than patients with SNCG-negative tumors. Overexpression of SNCG compromises normal mitotic checkpoint controls, resulting in multinucleation as well as faster cell growth. SNCG has also been shown to promote invasion and metastasis in in vitro assays as well as in animal models. SNCG overexpression also interferes with drug-induced apoptotic responses. Expression of SNCG in cancer cells results in a more malignant phenotype with increased cell motility, enhanced transcriptional activity of steroid receptors and accelerated rate of chromosomal instability. Two closely located AP1 binding sites residing in the first intron of the SNCG gene are important regulators of the promoter activity. Other factors regulating SNCG expression are methylation-demethylation of exon and post-transcriptional regulation by microRNAs.
NCBI: 6623 MIM: 602998 HGNC: 11141 Ensembl: ENSG00000173267
dbSNP: 6623 ClinVar: 6623 TCGA: ENSG00000173267 COSMIC: SNCG
Andrei Surguchov
SNCG (synuclein, gamma (breast cancer-specific protein 1))
Atlas Genet Cytogenet Oncol Haematol. 2014-06-01
Online version: http://atlasgeneticsoncology.org/gene/42343/gene-explorer/
2007-06-01 SNCG (synuclein, gamma (breast cancer-specific protein 1)) by Artur Czekierdowski,Sylwia Czekierdowska  Affiliation